Literature DB >> 14638963

Vagus nerve stimulation for essential tremor: a pilot efficacy and safety trial.

A Handforth1, W G Ondo, S Tatter, G W Mathern, R K Simpson, F Walker, J P Sutton, J P Hubble, J Jankovic.   

Abstract

OBJECTIVE: To assess the safety and efficacy of vagus nerve stimulation (VNS) for essential tremor (ET).
METHODS: This was a pilot open-treatment trial at three centers, with masked videotape tremor assessments. Inclusion required a severity score of 3 or 4 on the Tremor Rating Scale (TRS) in one or both hands. At baseline, tremor was assessed with TRS and Unified Tremor Rating Assessment (UTRA), accelerometry, and a videotape protocol. The VNS device was implanted with leads placed around the left cervical vagus nerve. Stimulation was adjusted over 4 weeks before the repeat tremor assessments. Two raters masked to the study visit scored the videotapes.
RESULTS: Nine subjects participated, with a mean age of 65 years and a mean age at onset of tremor of 24. Investigators rated hand tremor as mildly improved (TRS 2.3 +/- 0.7 during VNS vs 3.0 +/- 0.4 during baseline, p = 0.06). Accelerometry-measured total power improved 50.2 +/- 31.8% (p < 0.01). Videotape tremor scores were highly correlated between the masked raters and revealed no changes in tremor scores with treatment. VNS was well tolerated, with the most common adverse events being stimulation related.
CONCLUSIONS: VNS was judged by investigators to mildly improve upper extremity tremor. This finding was not confirmed in videotape scoring by masked raters. VNS is not likely to have a clinically meaningful effect on ET.

Entities:  

Mesh:

Year:  2003        PMID: 14638963     DOI: 10.1212/01.wnl.0000094355.51119.d2

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

1.  Vagus nerve stimulation effective for focal motor seizures and focal interictal parkinsonian symptoms. A case report.

Authors:  S Bokkala-Pinninti; N Pinninti; S Jenssen
Journal:  J Neurol       Date:  2007-11-14       Impact factor: 4.849

2.  Vagal nerve stimulation for pharmacoresistant epilepsy in children.

Authors:  Jason S Hauptman; Gary W Mathern
Journal:  Surg Neurol Int       Date:  2012-10-31

3.  A master protocol to investigate a novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia.

Authors:  T Fields; M Patterson; T Bremova-Ertl; G Belcher; I Billington; G C Churchill; W Davis; W Evans; S Flint; A Galione; U Granzer; J Greenfield; R Karl; R Kay; D Lewi; T Mathieson; T Meyer; D Pangonis; F M Platt; L Tsang; C Verburg; M Factor; M Strupp
Journal:  Trials       Date:  2021-01-22       Impact factor: 2.279

4.  Video Rating in Neurodegenerative Disease Clinical Trials: The Experience of PRION-1.

Authors:  Christopher Carswell; Michael Rañopa; Suvankar Pal; Rebecca Macfarlane; Durre Siddique; Dafydd Thomas; Tom Webb; Steve Wroe; Sarah Walker; Janet Darbyshire; John Collinge; Simon Mead; Peter Rudge
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2012-08-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.